FDA introduces a new program to expedite deployment of potential coronavirus treatments

FDA introduces a new program to expedite deployment of potential coronavirus treatments

4 years ago
Anonymous $9CO2RSACsf

https://techcrunch.com/2020/03/31/fda-introduces-a-new-program-to-expedite-deployment-of-potential-coronavirus-treatments/

The U.S. Food and Drug Administration (FDA) announced a new program today that’s designed to foster close collaboration between public and private organizations in order to “bring coronavirus treatments to market as fast as possible,” according to U.S. Department of Health & Human Services Secretary Alex Azar in a press release. The program, dubbed the “Coronavirus Treatment Acceleration Program, or CTAP, will see the FDA redeploy resources and personnel with an eye towards providing private companies, researchers and scientists with “regulatory advice, guidance and technical assistance as quickly as possible.”

Based on the information provided by the agency, it sounds like CTAP is a formalization of a lot of the work that was already being done within the FDA to reduce the burden placed on companies and scientists looking to field trials and take the steps required by the administration to qualify new treatments and therapies for use.

FDA introduces a new program to expedite deployment of potential coronavirus treatments

Mar 31, 2020, 9:27pm UTC
https://techcrunch.com/2020/03/31/fda-introduces-a-new-program-to-expedite-deployment-of-potential-coronavirus-treatments/ > The U.S. Food and Drug Administration (FDA) announced a new program today that’s designed to foster close collaboration between public and private organizations in order to “bring coronavirus treatments to market as fast as possible,” according to U.S. Department of Health & Human Services Secretary Alex Azar in a press release. The program, dubbed the “Coronavirus Treatment Acceleration Program, or CTAP, will see the FDA redeploy resources and personnel with an eye towards providing private companies, researchers and scientists with “regulatory advice, guidance and technical assistance as quickly as possible.” > Based on the information provided by the agency, it sounds like CTAP is a formalization of a lot of the work that was already being done within the FDA to reduce the burden placed on companies and scientists looking to field trials and take the steps required by the administration to qualify new treatments and therapies for use.